Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population터키 노인 인구에서 SARS-CoV-2 비활성화 백신(CoronaVac)에 대한 항체 반응Article Published on 2022-05-012022-09-11 Journal: Age and Ageing [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affecting Anti-spike anti-Spike IgG Antibody Response association best Charlson Comorbidity Index clinical Comorbidity Comprehensive CoronaVac COVID-19 vaccine defined Factor frailty geriatric assessment group IgG antibodies IgG antibody Inactivated vaccine individual Infection influence knowledge neutralising neutralising antibody Older older people Patient patients performed Prevalence response duration SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike-specific SARS-CoV-2 spike-specific IgG antibodies scale second dose seronegative seropositive Seropositivity significantly higher Sinovac specific IgG antibodies the antibody response the vaccine three group three groups U/mL vaccination [DOI] 10.1093/ageing/afac088 PMC 바로가기 [Article Type] Article
An overview on inactivated and live-attenuated SARS-CoV-2 vaccines불활성화 및 약독화 SARS-CoV-2 백신에 대한 개요Review Published on 2022-05-012022-09-11 Journal: Journal of Clinical Laboratory Analysis [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse effects antigenic attenuated vaccine benefit Bharat Cell culture Cellular immune response China clinical trials component components coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine deaths effective Efficiency Features followed by Health Organization humoral Humoral and cellular immune responses immune responses inactivated Inactivated vaccine Infection landscape Phase 3 produced producing Record report review Safe SARS-CoV-2 SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus similarity Sinopharm Sinovac storage the vaccine Transport trials Vaccine vaccine candidate vaccine platform Vaccines virion virus particle WHO World Health Organization worldwide pandemic Wuhan [DOI] 10.1002/jcla.24418 PMC 바로가기 [Article Type] Review
Elevated CD21 low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency증가된 CD21 낮은 B 세포 빈도는 공통 가변성 면역결핍증 환자에서 SARS-CoV-2에 대한 화이자-바이오엔텍 BNT162b2 mRNA 백신에 대한 면역 저하의 지표입니다Clinical Trial Published on 2022-05-012022-09-12 Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] affected Against analyzed antibody B-cell baseline BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 mRNA vaccine CD21 CD21low B-cells CD4 cell count central memory clinical trial cohort of patient common correlated COVID-19 COVID-19 vaccination CVID demonstrated dose Frequency healthy control Humoral immunity IFN-γ IgG immune response immunocompromised individuals immunodeficiency Limited median titer memory B-cell Open-label Patient patients patients with CVID Pfizer-BioNTech Pfizer-BioNTech BNT162b2 mRNA vaccine Poor positive proportion reached reduced response SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike-specific second dose selected seroconverted seronegative significantly single-center T cell response T-cell the vaccine threshold vaccine responses variable were assessed [DOI] 10.1007/s10875-022-01244-2 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards modelObservational Study Published on 2022-05-012022-10-05 Journal: Age and Ageing [Category] COVID19(2023년), SARS, 임상, [키워드] adjusted hazard ratio adverse outcome Against BNT162b2 calculated Care COVID-19 COVID-19-related death Cox proportional hazard death defined died dose doses Effectiveness England hazard high risk highest individuals Infection intervals moderate mortality data of BNT162b2 Older older people Positive test positive test result protection provided relative SARS CoV-2 SARS-CoV-2 second dose study period Symptom tested the vaccine vaccination Vaccine vaccine effectiveness [DOI] 10.1093/ageing/afac115 PMC 바로가기 [Article Type] Observational Study
Shedding light on the toxicity of SARS-CoV-2-derived peptide in non-target COVID-19 organisms: A study involving inbred and outbred mice비표적 COVID-19 유기체에서 SARS-CoV-2 유래 펩타이드의 독성에 대한 조명: 근친교배 및 근친교배 마우스를 대상으로 한 연구Article Published on 2022-05-012022-09-11 Journal: Neurotoxicology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 유전자 메커니즘, [키워드] acetylcholinesterase activated administration alteration animals antidepressant antioxidant anxiolytic applied biochemical Biomarker Brain C57Bl/6 J mice catalase consequence COVID-19 demonstrated depressive dismutase dispersion Effect Environmental Toxicology evaluate evaluated Evidence evidence of exposure to Field test genetic profile greater homeostasis hydrogen hydrogen peroxide Impact Laboratory locomotor maintain male mammalian mechanism memory memory deficit mice natural environments open oxidative stress Pandemic COVID-19 PCA peptide Principal component principal component analysis Protein Proteins provide reactive reduction in Research response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 particle SARS-CoV-2 particles sensitivity shedding Spike protein Superoxide Superoxide Dismutase Swiss mice. the Spike the vaccine Therapeutic strategies therapeutic strategy Toxicity Viral [DOI] 10.1016/j.neuro.2022.03.012 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialHIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험Clinical Trial Published on 2022-05-012022-09-12 Journal: The Lancet. HIV [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 amplification angiotensin-converting enzyme 2 anti-Spike IgG antibody Antiretroviral therapy article assigned baseline clinical Coalition Cohort COVID-19 COVID-19 vaccine death dosage Efficacy and safety ELISA endpoints enrolled enrolment evaluated first vaccination geometric mean titre GMT GMTs HIV-1 HIV-1 viral HIV-negative humoral immune response immunogenicity increased risk individual injection interim analysis intervention group Intramuscular injection less Local Matrix-M Melinda Gate multicentre neutralising antibody titres Novavax NVX-CoV2373 NVX-CoV2373 vaccine observer-blinded occurred PACTR202009726132275 participant Participants paucity of data Placebo placebo-controlled provided randomised Randomly reactive receive Recombinant spike protein Registered registry remained reported safety analysis SARS-CoV-2 SARS-CoV-2 nucleic acid SCR SCRs second vaccination Serious Adverse Event Serious Adverse Events seroconversion rate serostatus South Africa stratified study group Support systemic adverse event the placebo group the vaccine Trial vaccination Vaccine vaccine immunogenicity Volume was used were assessed [DOI] 10.1016/S2352-3018(22)00041-8 PMC 바로가기 [Article Type] Clinical Trial
Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 20212021년 11월-12월 프랑스 마르세유에서 발생한 최초의 1119 SARS-CoV-2 Omicron 변종 사례의 특성Article Published on 2022-05-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-SARS-CoV-2 antibodies booster dose coronavirus COVID-19 death Delta diagnosed died dose France Hospitalization Hospitalized Infection intensive care intensive care unit Marseille omicron one patient Patient required SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus the vaccine vaccination Vaccination Status Vaccine variant [DOI] 10.1002/jmv.27613 PMC 바로가기 [Article Type] Article
Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipientsResearch article Published on 2022-05-012022-10-05 Journal: Vaccine [Category] COVID19(2023년), SARS, 임상, [키워드] Acute kidney injury acute respiratory distress Admission all-cause mortality BNT162b2 case-control study Clinical outcome clinician Complication control group CoronaVac COVID COVID-19 COVID-19 vaccine Cytokine storm death decrease described diagnosed diagnosed with COVID-19 died difference dose Effectiveness Efficacy Endpoint Evidence excluded fatal disease FIVE Follow-up Hospitalization Hospitalized ICU in healthy individuals intensive care kidney transplant kidney transplant recipient kidney transplant recipients Kidney transplantation material median age men nine Occurrence participant Patient patients Prevent Protective Result SARS-CoV-2 SARS-COV-2 infection syndrome the patient the vaccine Treatment Vaccine vaccine effectiveness with COVID-19 [DOI] 10.1016/j.vaccine.2022.04.066 [Article Type] Research article
The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: A systematic review and meta-analysisDelta 변이에 의한 코로나19에 대한 mRNA-1273 백신의 효과: 체계적인 검토 및 메타분석Meta-Analysis Published on 2022-05-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval administration B.1.617.2 caused Chain Reaction coronavirus COVID-19 database Delta delta variant disease disease control Effectiveness eligible first dose identify indicated meta-analyses Meta-analysis meta-analysis model mRNA mRNA-1273 mRNA-1273 vaccine observational studies observational study Odds ratio offer Pathogenesis polymerase chain reaction Prevent random-effect reduced reported respiratory tract reverse transcription Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 second dose strain systematic literature search systematic review the vaccine vaccination Vaccine vaccines/vaccine strains virus virus classification was performed was used [DOI] 10.1002/jmv.27568 PMC 바로가기 [Article Type] Meta-Analysis
Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi ArabiaResearch article Published on 2022-05-012022-10-05 Journal: Journal of infection and public health [Category] COVID19(2023년), SARS, 임상, [키워드] Administered adverse event AEs approved average AZD1222 BNT162b2 body mass index Breakthrough infection Clinical data clinical trials co-morbidity Cohort collected conducted COVID-19 COVID-19 infection COVID-19 vaccine demographics dose Effect Effectiveness eight fatigue Fever Follow-up had no headache higher risk Infection injection site pain interactions Kingdom large cohort majority male median age medical records myalgia National obese obesity Occurrence organ outcome pandemic parameters participant prospective cohort study real-world data reported Result risk factor Saudi Arabia side single dose Single-dose social interaction subject subjects the vaccine Travel vaccination Vaccine Vaccines [DOI] 10.1016/j.jiph.2022.04.001 [Article Type] Research article